What did @thepepphixofficial actually say?
The creator, who identifies as the founder of a multi-million dollar skincare brand, made a hierarchy argument: GHK-Cu topical serums are nearly useless, oral GHK-Cu is marginally better but not worth it, and subcutaneous injections are the only form worth using. Her core claim is that topical peptides cannot penetrate skin deeply enough for collagen remodeling, that oral GHK-Cu gets degraded by digestion, and that injections deliver "100% bioavailability." She does carve out a small exception for what she calls "drone copper peptide serums" from brands like Peach and Lily or Medicate, but says even those only produce mild relaxation of fine lines, not true collagen remodeling.
She is speaking from a commercial position, which is worth keeping in mind. She sells skincare products, but she is arguing against the topical category she presumably operates in, which at least signals she is not simply pushing her own product line here.
Does the science back this up?
Partially, but the picture is more complicated than she presents. The bioavailability claim for injections is directionally correct. The dismissal of topicals is too absolute. And the oral bioavailability argument has real nuance she skips over.
On topicals: GHK-Cu is a small tripeptide with a molecular weight of roughly 340 daltons, well under the 500-dalton rule of thumb for skin penetration. Some in vitro data suggests it can reach the dermis. A study by Pickart and Margolina (2018, Biomolecules) documented GHK-Cu's ability to stimulate collagen synthesis, but much of this work was done in cell cultures or animal models, not in controlled human clinical trials comparing delivery routes. The creator's framing that topical GHK-Cu does "absolutely anything" is an overstatement in the negative direction.
On oral GHK-Cu: she is right that peptides face enzymatic degradation in the GI tract. However, the idea that zero collagen remodeling occurs orally is not established. Some collagen peptides survive partial digestion and generate bioactive fragments. The oral GHK-Cu literature specifically is thin.
On injections: subcutaneous peptide delivery does bypass the skin and gut barriers, and bioavailability is substantially higher than topical routes. "100% bioavailable" is a common but technically imprecise claim even for injections.
What did they get wrong (or right)?
She got the general delivery hierarchy right. Injections do outperform topicals and oral routes for systemic peptide action. That part is defensible.
Where she overshoots: saying topical GHK-Cu does "absolutely anything" is too strong. A 2015 study by Finkley et al. (Journal of Wound Care) found topical copper peptide formulations improved skin elasticity and density in human subjects. The effect size was modest, but it was not zero. Dismissing the entire topical category categorically misrepresents the available, if limited, evidence.
Her "100% bioavailable" claim for injections is also sloppy. Bioavailability for subcutaneous peptide injections is high, often cited in the 80-95% range depending on the compound, but 100% is a number reserved for IV administration in pharmacokinetics. It is a minor but meaningful error for someone presenting themselves as a formulation science expert.
Her characterization of "drone delivery" serums is interesting but not well-supported by public clinical data. The technology exists conceptually, but independent peer-reviewed evidence for these specific brands' efficacy claims is not established in the published literature.
What should you actually know?
GHK-Cu is a legitimate area of research, but the hype on all delivery formats outpaces the clinical evidence. The creator is right that delivery route matters enormously for peptides. The science on GHK-Cu injection therapy in humans specifically is still early-stage. Most robust GHK-Cu mechanistic data comes from in vitro or animal studies, not large randomized controlled trials in people.
If you are considering GHK-Cu injections, this is a decision that belongs in a clinical conversation with a licensed provider, not a TikTok comment section. Compounded peptide injectables carry regulatory and quality-control considerations that are entirely absent from this video. The FDA has taken enforcement actions related to compounded peptides, and the risk-benefit picture is not as simple as "100% bioavailable, good for everything."
- Topical peptides are not automatically useless. Molecular weight and formulation chemistry both affect penetration depth.
- Oral peptide bioavailability is genuinely limited but not necessarily zero.
- Subcutaneous injection does provide higher systemic exposure than topical or oral routes for most peptides.
- "100% bioavailable" for subcutaneous administration is pharmacologically incorrect. IV is the 100% baseline.
- Human clinical trial data on GHK-Cu across all delivery routes remains limited as of 2024.